Skip to main content

STAT reports that Artiva is shutting down its autoimmune cell therapy trial after two patients died. The news comes as drugmakers have shown interest in using cancer therapy strategies for autoimmune conditions, but these recent deaths have raised new concerns about safety and risk.

For senior executives in biotech and pharma, this development signals increased scrutiny on adapting cancer treatments for other diseases. Companies may need to reassess trial protocols and risk management processes. The outcome may affect investor confidence and regulatory expectations in the sector.

Artiva shuts autoimmune cell therapy trial after two patient deaths

Missouri’s attorney general has told Eli Lilly to stop making hospitals provide claims data to access discounted medicines under the federal 340B programme, according to STAT. The warning reflects a broader trend of state officials challenging pharmaceutical companies’ requirements tied to drug discount access.

This development matters for pharma and healthcare executives because it signals a shift in how states may regulate data collection and discount eligibility. More states could follow Missouri’s lead, increasing compliance risks and operational uncertainty for drugmakers and hospitals alike.

Missouri AG tells Lilly to halt hospital data demands for 340B discounts

STAT reports that the FDA has provided new details on an accelerated approval pathway for personalised gene therapies. Rare disease advocates praised the announcement, suggesting it could improve access to treatments for patients with limited options.

This update matters for pharma and biotech leaders, as regulatory changes may affect the speed and cost of bringing new therapies to market. Companies should monitor further guidance from the FDA and assess how these changes could influence development strategies.

FDA details faster approval route for personalised gene therapies

A House lawmaker is investigating whether the three largest pharmacy benefit managers (PBMs) targeted independent pharmacies with retaliatory audits, according to STAT. The inquiry focuses on whether these audits were used as a punitive measure against smaller pharmacy operators.

This investigation matters for healthcare and pharmaceutical leaders because PBMs play a central role in drug pricing and pharmacy reimbursement. Increased scrutiny may lead to regulatory changes or shifts in audit practices, affecting relationships with independent pharmacies and supply chain management.

US House investigates PBMs over audits of independent pharmacies

The Trump administration has removed several security, privacy and transparency requirements for vendors of electronic health record (EHR) software, according to STAT. The move changes the regulatory obligations for companies supplying hospitals with EHR systems.

This adjustment may affect how hospitals and health tech firms manage risk and compliance. Leaders in these sectors should review their security protocols and supplier contracts to assess any new exposure. Ongoing monitoring of regulatory guidance is advised.

HHS eases security and privacy rules for hospital EHR software vendors

STAT reports that nonprofit Bon Secours Mercy Health has agreed to acquire a surgery centre chain in a $5.7 billion deal. The transaction would make the Catholic health system one of the largest operators of outpatient surgery centres in the US.

This scale could affect how hospitals, insurers, and independent practices compete for outpatient procedures. Senior executives should consider the impact on referral flows, pricing power, and future consolidation in the sector. The deal may also prompt regulatory interest in market concentration.

Bon Secours Mercy Health buys surgery centre chain in $5.7 billion deal

Back in 2009, sequencing Euan Ashley’s entire genome required nearly a year and the effort of 30 specialists. Fast forward to 2026, and Claude accomplished the same task in just 30 minutes, costing approximately $5. This drastic reduction in time and expense highlights the incredible advancements in genomic technology. However, with rapid analysis capabilities now accessible, establishing clear standards for interpreting and using these results is becoming increasingly critical.

From Year-Long to Minutes: The Revolution in Genome Analysis and the Need for Standardized Interpretation

Federal health authorities are launching new strategies to enhance the pace of clinical research, aiming to stay competitive on a global scale, especially against countries like China.

HHS Unveils New Initiatives to Accelerate Clinical Trials Using AI

At a MAHA Institute event, Kennedy and other experts emphasized the importance of making health data more accessible. They highlighted how unlocking this data can accelerate research on vaccines, chronic diseases, and autism, ultimately benefiting public health outcomes.

MAHA Advocates for Enhanced Accessibility of Health Data

Beam Therapeutics claims that one of its scientists misappropriated proprietary gene-editing technology to establish a Chinese biotech company, which has subsequently secured venture capital investment.

Beam Therapeutics Files Lawsuit Against Chinese Biotech Startup Over Alleged IP Theft